Drug-induced long QT syndrome (diLQTS) and congenital LQTS (cLQTS) share many features, and both syndromes can result in life-threatening torsades de pointes (TdP). Our understanding of their mechanistic and genetic similarities has led to their improved clinical management. However, our inability to prevent diLQTS has resulted in removal of many medicines from the market and from development. This study reviews how knowledge about diLQTS developed, the significance and mechanisms underlying TdP, and its clinical and genetic risk factors, which raise the possibility of facilitating prevention.
T here are few instances in medical history of a single clinical entity that has been as disruptive for so many diverse groups and individual patients as drug-induced long QT syndrome (diLQTS) (1, 2) . diLQTS is associated with a special form of ventricular tachycardia (VT) called This study reviews how knowledge about diLQTS developed, the significance and mechanisms underlying TdP, and its clinical and genetic risk factors, which raise the possibility of facilitating prevention.
We also review what has been achieved by the creation of an independent organization aimed at evaluating the evidence and identifying drugs that have the potential of favoring or causing TdP and its success in impacting on therapeutic choices for patients potentially at risk. We conclude with our views on future directions and approaches to prevention.
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HISTORICAL BACKGROUND
It all started with quinidine syncope. To the best of our knowledge, the first such report goes back almost 100 years (3) and was eventually followed by several others almost 40 years later (4, 5) . Cardiologists were initially focused on quinidine because it was the only drug effective for the management of atrial fibrillation (6) , and this prompted the realization that these dramatic episodes of syncope had 2 key features: prolongation of the QT interval and occurrence of TdP VT.
It was only in 1982, in the pre-genetic era, that Schwartz and Moss (7) advanced the hypothesis that these events could represent a "forme fruste" of the congenital long QT syndrome (cLQTS) (8, 9) , thus suggesting that patients with a borderline QT prolongation might have been predisposed to develop TdP when treated with drugs sharing some pharmacological actions with quinidine. We will return to this point when discussing the genetic basis for diLQTS.
In 1966, the French cardiologist Dessertenne (10) described the electrocardiographic pattern of VT, which he named torsades de pointes ("twisting of the points"), and noted its association with a markedly prolonged QT interval ( Figure 1 ). As most of the initial cases of TdP reported in the 1970s and 1980s were observed in patients treated for cardiac arrhythmia, it was generally assumed to be a relatively rare form of proarrhythmic event, mainly confined to antiarrhythmic drugs, such as quinidine, disopyramide, and procainamide, that prolong the QT interval. However, in 1990, the medical community's attitude toward TdP changed dramatically when it became known that noncardiac drugs taken by millions of patients, such as the nonsedating antihistamine terfenadine, could also cause QT prolongation and TdP (11).
Shortly thereafter, reports emerged of TdP with another antihistamine, astemizole, followed by the gastrointestinal drug cisapride, the antibiotic erythromycin (12), the opiates levomethadyl and methadone (13), a drug for hypercholesterolemia, probucol, and many other nonantiarrhythmic drugs, including antifungal agents and anticancer drugs. It became clear that TdP could occur with drugs in any therapeutic class, and, despite its uncommon occurrence, the incidence for many drugs became intolerable, prompting removal of several from the market (14) .
Since 1989, 14 clinically important drugs have been removed from the market due to TdP (14) , and development of an unknown number has been stopped due to concern that they might pose a risk of causing QT prolongation and TdP. In the 1990s, (17) (18) (19) . As discussed previously, much of our understanding comes from similarities between the characteristics of cLQTS (8, 9) and the actions of the medications that cause TdP, especially their shared ability to block I Kr , a major cardiac potassium current contributing to the repolarization phase of the cardiac action potential. Other causes of acquired QT prolongation include electrolyte abnormalities (hypokalemia, hypomagnesemia, and hypocalcemia), hypothyroidism, hypothermia, and extreme bradycardia, any of which can cause TdP or contribute to the risk of drug-induced TdP (17) .
Although QT prolongation is an essential first step in TdP, it is usually not considered sufficient to induce TdP. Nonetheless, there is an increased risk for TdP whenever QTc exceeds 500 ms and whenever a drug increases QTc by >60 ms to 70 ms, especially when the increase occurs rapidly (17) . QT interval prolongation is particularly proarrhythmic when associated with increased dispersion in the recovery of excitability (20) . Additional steps appear to be Predicting and Preventing Drug-Induced LQTS A P R I L 5 , 2 0 1 6 : 1 6 3 9 -5 0 required for TdP to occur; for example, the development of early afterdepolarizations that are calciummediated and were identified as a cause of reentrant arrhythmias in vitro models (19 (23, 24) . Also, numerous drugs with the ability to cause QT prolongation have been associated with a higher than expected incidence of sudden death (25) (26) (27) (28) (29) . However, the fact that only a subset of patients who develop drug-induced QT prolongation experience TdP or death suggests that QT prolongation alone is not a perfect biomarker for predicting TdP (29) and must be combined with other known risk factors for TdP to have clinical utility (30) .
Be that as it may, QT prolongation remains the single most useful warning signal to alert for the risk of TdP.
CredibleMeds RISK CATEGORIZATION OF DRUGS
In 1999, because of increased concern for the poten- 
EPIDEMIOLOGY OF TdP AND DEATH ASSOCIATED WITH QT-PROLONGING DRUGS
For specific drugs, the incidence of TdP is difficult to quantify. It varies greatly and ranges from extremely low for many of the macrolide antibiotics (36,37) to 1.5% to 9% for quinidine (38, 39) and from 0.5% to 1% for drugs such as sotalol (17) and azimilide (40) . Because of these differences, the overall incidence of TdP in a given population will depend on the relative risk of the drugs prescribed and the frequency of their use. For example, a cardiac care unit (CCU) population is frequently prescribed antiarrhythmic drugs and will likely have a much higher frequency of TdP than would be seen in a routine outpatient population. Table 1 .
DRUG-INDUCED LQTS VERSUS CONGENITAL LQTS
The fact that the life-threatening arrhythmia of diLQTS and of cLQTS are the same (TdP) and that both conditions are associated with major prolongation of the QT interval, often with bizarre morphology of the T-wave, should have immediately raised the issue of a relationship between the 2 conditions. However, as briefly alluded to in the introduction, it was only in 1982 that Schwartz and Moss (7) first made such a suggestion, when they proposed that diLQTS could be a "forme fruste" of cLQTS.
It took several years for their hypothesis to be confirmed and accepted. Indeed, this novel concept remained dormant until the first major genes for This was the theory, but, as always, facts and evidence were needed. An elderly female patient with documented cardiac arrest related to the I Kr -blocking drug cisapride was found to carry a KCNQ1 mutation causing a loss in the I Ks repolarizing current (59) .
While this patient was taking cisapride, her QTc was markedly prolonged, but after cisapride withdrawal, the QTc normalized. She had 2 sons with normal QT intervals but who were also carriers of the mutation.
This was the first evidence that, as proposed by 
Concomitant therapy with another QT-prolonging drug
Concomitant therapy with a potassium-wasting diuretic agent Concomitant drug therapy that blocks the metabolism of a QT-prolonging drug Development of renal failure in a patient treated with a QT-prolonging drug that requires renal elimination (e.g., sotalol)
Development of liver failure in a patient treated with a QT-prolonging drug that requires hepatic metabolism for clearance (e.g., methadone)
Development of vomiting or diarrhea resulting in electrolyte disturbances that potentiate the QT-prolonging effects of drugs such as antiemetic agents or antibiotics
Extended therapy with a proton pump inhibitor that leads to hypomagnesemia and/or hypokalemia Therapy with a beta-blocker or ivabradine that slows heart rate and thereby prolongs the QT interval.
Excessive titration to high dosage for a QT-prolonging drug due to lack of desired clinical response (e.g., methadone)
Depression causing attempted suicide with toxic doses of QT-prolonging drugs (e.g., antipsychotics and antidepressants, among others)
Schwartz and Moss (7), some cases of diLQTS with life-threatening arrhythmias may be a "forme fruste"
of cLQTS with an apparently normal baseline QTc. The most recent data, from a comparison of 188 diLQTS patients with more than 1,000 cLQTS patients incidence of TdP. To improve the acceptance of alerts and the effectiveness of CDSS overall, an expert panel has recommended that CDSS should only provide clinically relevant and essential information at the time when a decision is being made, without overwhelming the decision makers with more information than they need (70) . Moving away from the use of alerts to signal prescribing errors, the concept of "medical autopilots" has been suggested as a preferred approach for CDSS (71) . These programs will monitor the electronic medical record and send signals to guide prescribers toward decisions that result in maximum benefit and minimal risk of TdP.
Hopefully, in the near future, a CDSS with these characteristics will be able to prevent TdP by incorporating all of the clinical and genomic risk factors that we know can contribute to a person's risk of TdP. 
CONCLUSIONS

